Why Jupiter Neurosciences, Inc.’s (JUNS) Stock Is Down 6.67%
As of Monday, November 03, Jupiter Neurosciences, Inc.’s JUNS share price has dipped by 6.67%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson’s disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer’s disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Commentary & Analysis
Why Jupiter Neurosciences, Inc.’s (JUNS) Stock Is Down 11.18%
As of Wednesday, October 29, Jupiter Neurosciences, Inc.’s JUNS share price has dipped by 11.18%, which has investors questioning if this is right time to buy.Tudor Pop
Why Jupiter Neurosciences, Inc.’s (JUNS) Stock Is Up 10.46%
As of Monday, October 27, Jupiter Neurosciences, Inc.’s JUNS share price has surged by 10.46%, which has investors questioning if this is right time to sell.Tudor Pop
Why Jupiter Neurosciences, Inc.’s (JUNS) Stock Is Up 5.03%
As of Monday, October 20, Jupiter Neurosciences, Inc.’s JUNS share price has surged by 5.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Jupiter Neurosciences, Inc.’s (JUNS) Stock Is Up 11.84%
As of Thursday, October 16, Jupiter Neurosciences, Inc.’s JUNS share price has surged by 11.84%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | JUNS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.0 | $587.7 | 2% |
|
| Shares Out (Mil) | 0.5 | 44.5 | 2% |
|
| Institutional Ownership | 9.8% | 84.6% | 7% |
|
| Float (Mil) | 0.4 | 46.8 | 0% |
|
| Beta | na | 0.69 | na |
|
| Avg Daily Volume (000s) | 87 | 361 | 33% |
|
| Price Change (52-week) |
(94.4%) | 66.7% | 3% |
|
| Growth | JUNS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (38.3%) | (1.4%) | 10% |
|
| EPS (5yr) | (26.9%) | 14.9% | 9 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (43.7%) | (14.9%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | JUNS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $276 | na |
|
| Net Income (TTM) (Mil) | ($9) | ($11) | 30% |
|
| EPS (TTM) | ($19.574) | ($0.700) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($6) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $5 | $309 | 6% |
|
| Valuation | JUNS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.89 | na |
|
| P/E | na | 17.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | JUNS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.5% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (206.0%) | (22.5%) | 2% |
|
| ROE | na | (19.8%) | na |
|
| Liabilities to Assets | 170.5% | 32.4% | 98% |
|
| F-Score | 1 | 3 | 1% |
|
Jupiter Neurosciences, Inc. did not pass any screens on 8/14/2026.
